A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases

References

• Rebecca Siegel M, Deepa Naishadham M, MS, Ahmedin Jemal D, PhD. Cancer Statistics, 2013. CA: A Cancer Journal for Clinicians 2013:11-30.
   Google Scholar
• Sanoff HK SD, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008:5721-7; PMID:19001325; http://dx.doi.org/10.1200/JCO.2008.17.7147
   PubMed Web of Science ®Google Scholar
• Benson A, Bekaii-Saab T, Chan E, Chen Y-J, Choti MA, Cooper HS, Engstrom PF, Enzinger PC, Fakih M, Fenton MJ et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer National Comprehensive Cancer Network, Inc. Version 3.2013. 2013: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
   Google Scholar
• Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26:3291-310; PMID:17496923; http://dx.doi.org/10.1038/sj.onc.1210422
   PubMed Web of Science ®Google Scholar
• Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol 2005; 16:189-94; PMID:15668269; http://dx.doi.org/10.1093/annonc/mdi057
   PubMed Web of Science ®Google Scholar
• Ciardiello F TG. EGFR antagonists in cancer treatment. Eng J Med 2008:1160-74; PMID:18337605; http://dx.doi.org/10.1056/NEJMra0707704
   PubMed Web of Science ®Google Scholar
• Amado RG WM, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22:1535-46; PMID:21228335; http://dx.doi.org/10.1093/annonc/mdq632
   PubMed Web of Science ®Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27:663-71; PMID:19114683; http://dx.doi.org/10.1200/JCO.2008.20.8397
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29:2011-9; PMID:21502544; http://dx.doi.org/10.1200/JCO.2010.33.5091
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019
   PubMed Web of Science ®Google Scholar
• Peeters M PT, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010:4706-13; PMID:20921462; http://dx.doi.org/10.1200/JCO.2009.27.6055
   PubMed Web of Science ®Google Scholar
• Giusti RM SK, Pilaro AM, Fuchs C, Cordoba-Rodriguez R, Koti K, Rothmann M, Men AY, Zhao H, Hughes M, Keegan P, et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008:1296-302; PMID:18316547; http://dx.doi.org/10.1158/1078-0432.CCR-07-1354
   PubMed Web of Science ®Google Scholar
• Van Cutsem E PM, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658-64; PMID:17470858; http://dx.doi.org/10.1200/JCO.2006.08.1620
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065-75; PMID:25088940; http://dx.doi.org/10.1016/S1470-2045(14)70330-4
   PubMed Web of Science ®Google Scholar
• Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, et al. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. The oncologist 2012; 17:14; PMID:22210091
   PubMed Web of Science ®Google Scholar
• Montagut C, Bellosillo B, Gonzalez I, Martinez A, Dalmases A, Iglesias M, et al. Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer. J Clin Oncol 2014; 32: Suppl; abstr 3526. http://meetinglibrary.asco.org/content/133355-144
   Web of Science ®Google Scholar
• Sonoda H, Mekata E, Tomoharu S, Endo Y, Tani T. Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution. Oncol Lett 2013:1331-4; PMID:23599789
   PubMed Web of Science ®Google Scholar
• Peeters M PT, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 2009:29-39; PMID:19144681; http://dx.doi.org/10.1634/theoncologist.2008-0167
   PubMed Web of Science ®Google Scholar
• Vincenzi B SD, Tonini G. New issues on cetuximab mechanism of action in epidermal growth factor receptor - negative colorectal cancer: the role of vascular endothelial growth factor. J Clin Oncol 2006:1957-8; PMID:16622275; http://dx.doi.org/10.1200/JCO.2005.05.0450
   PubMed Web of Science ®Google Scholar
• Squibb B-M. Erbitux (Cetuximab) package insert. New York, NY, and Princeton, NJ: ImClone Systems Incorporated, 2006.
   Google Scholar
• Inc. A. Vectibix (Panitumumab) package insert. Thousand Oaks, CA, 2006.
   Google Scholar
• Heun J, Holen K. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report. Clin Colorectal Cancer 2007; 6:529-31; PMID:17553202; http://dx.doi.org/10.3816/CCC.2007.n.019
   PubMed Web of Science ®Google Scholar
• Helbling D, Borner M. Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Ann Oncol. England, 2007:963-4; PMID:17488734, http://dx.doi.org/10.1093/annonc/mdm130
   PubMed Web of Science ®Google Scholar
• Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J. Infusion reactions to the chimeric EGFR inhibitor cetuximab–change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol. England, 2011; 22:486-7; PMID:21239398
   PubMed Web of Science ®Google Scholar
• Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012:221-3; PMID:22270724; http://dx.doi.org/10.1038/nm.2609
   PubMed Web of Science ®Google Scholar
• Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice The Oncologist 2008:1270-5; PMID:19056857; http://dx.doi.org/10.1634/theoncologist.2008-0181
   PubMed Web of Science ®Google Scholar
• Baldus SE, Schaefer K-L, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010:790-9; PMID:20103678; http://dx.doi.org/10.1158/1078-0432.CCR-09-2446
   PubMed Web of Science ®Google Scholar
• Artale S, Sartore-Bianchi A, Veronese SM, Gambi V, Sarnataro CS, Gambacorta M, Lauricella C, Siena S. Mutations of KRAS and BRAF in Primary and Matched Metastatic Sites of Colorectal Cancer J Clin Oncol 2008:4217-9; PMID:18757341
   PubMed Web of Science ®Google Scholar
• Knijn N, Mekenkamp LJM, Klomp M, Vink-Börger ME, Tol J, Teerenstra S, Meijer JW, Tebar M, Riemersma S, van Krieken JH, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011:1020-6; PMID:21364579; http://dx.doi.org/10.1038/bjc.2011.26
   PubMed Web of Science ®Google Scholar
• Ishii M, Sugai T, Habano W, and S.-i. Nakamura S-i. Analysis of Ki-ras gene mutations within the same tumor using a single tumor crypt in colorectal carcinomas. J Gastroenterol 2014; 39:544-549. http://link.springer.com/article/10.1007/s00535-003-1340-3
   Google Scholar
• Ishii M, Sugai T, Habano W, Nakamura S. Analysis of Ki-ras gene mutations within the same tumor using a single tumor crypt in colorectal carcinomas. J Gastroenterol 2004; 39:544-9; PMID:15235871; http://dx.doi.org/10.1007/s00535-003-1340-3
   PubMed Web of Science ®Google Scholar
• Al-Mulla F, Going JJ, Sowden ET, Winter A, Pickford IR, Birnie GD. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 1998; 185:130-8; PMID:9713338; http://dx.doi.org/10.1002/(SICI)1096-9896(199806)185:2%3c130::AID-PATH85%3e3.0.CO;2-M
   PubMed Web of Science ®Google Scholar
• Oudejans JJ SR, Zoetmulder FA, Mooi WJ, Rodenhuis S. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer 1991:875-9; PMID:1959991; http://dx.doi.org/10.1002/ijc.2910490613
   PubMed Web of Science ®Google Scholar
• Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486:532-6; PMID:22722830
   PubMed Web of Science ®Google Scholar
• Diaz LA, Jr., Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486:537-40; PMID:22722843
   PubMed Web of Science ®Google Scholar